- $435.03m
- $314.29m
- $428.71m
- 95
- 51
- 46
- 69
2019 December 31st | R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 315 | 357 | 323 | 316 | 429 |
Cost of Revenue | |||||
Gross Profit | 82.9 | 95.1 | 91.6 | 155 | 146 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 305 | 335 | 299 | 238 | 419 |
Operating Profit | 9.82 | 21.9 | 24.1 | 77.8 | 10 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 5.98 | 22.4 | 23.7 | 77.5 | 18.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.38 | 14.8 | 16.1 | 56.5 | 13.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 4.17 | 13.2 | 29.2 | 87.8 | 19.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.69 | 11.7 | 27.5 | 85.9 | 19.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.108 | 0.449 | 0.492 | 2.16 | 0.491 |
Dividends per Share |